Press releaseGlobe Newswire
Milestone Pharmaceuticals
MIST · NASDAQ
$0.6482−$0.0545 (−7.76%)TodayMarket closed ·
Prev close $0.7027
Latest news
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
- News
Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
- Press releaseGlobe Newswire
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
- Press releaseBusiness Wire
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
- Press releaseGlobe Newswire
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- NewsDylan Berman
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales
- News
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial
- News
Earnings Scheduled For May 13, 2026
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
- Press releaseGlobe Newswire
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsVandana Singh
Why Milestone Pharma Stock Is Taking A Dive Today
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
- News
Earnings Scheduled For March 20, 2026
- NewsAvi Kapoor
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- Press releaseGlobe Newswire
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
- Press releaseBusiness Wire
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
- NewsVandana Singh
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
- News
Market-Moving News for December 15th
- Press releaseGlobe Newswire
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
- Press releaseGlobe Newswire
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
- Press releaseGlobe Newswire
Milestone® Pharmaceuticals to Present at Upcoming Conferences
- NewsAvi Kapoor
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
- NewsVandana Singh
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
- NewsAvi Kapoor
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
- Press releaseGlobe Newswire
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- Press releaseBusiness Wire
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
- NewsNabaparna Bhattacharya
Why Is Milestone Pharmaceuticals Stock Plunging Today?
- Press releaseGlobe Newswire
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
- Press releaseGlobe Newswire
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Press releaseGlobe Newswire
Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.